Xamic 500 mg

Description

Indications:

• In Medicine: Used for prophylaxis and treatment of hemoptysis, digestive hemorrhages, hemorrhagic syndromes in leukemia, cirrhosis, hemophilia, thrombocytopenic purpura, and accidents during thrombolytic therapy and transfusion.
• In Surgery: Prophylactic and antihemorrhagic therapy during surgeries, including pulmonary, cardiovascular, and abdominal procedures, as well as post-operative and traumatic shock.
• In Urology: Used for the prevention and treatment of hemorrhages during prostatic, vesical, and renal surgeries, including hematuria.
• In Obstetrics: Preventive and therapeutic treatment for post-partum hemorrhages, puerperium hemorrhages, hemorrhagic metropathies, functional menometrorrhagia, IUD-induced menorrhagia, and conditions like abruptio placentae and premature placenta detachment.
• In Otorhinolaryngology: Prophylaxis and therapy during tonsillectomies, specialist surgeries, and for conditions like epistaxis (nosebleeds).
• In Stomatology: Antihemorrhagic therapy during maxillofacial surgeries and tooth extractions.
• In Oncology: As supportive therapy to promote the formation of a fibrin capsule to inhibit the growth of ovarian tumors, manage ascites secondary to carcinoma, and reduce bleeding during surgical interventions.

Always consult a registered healthcare provider before use.

Pharmacology: Xamic contains Tranexamic Acid, a potent antifibrinolytic agent. It is up to 10 times more active than conventional hemostatics. Tranexamic Acid works by inhibiting plasminogen activation, reducing the breakdown of fibrin, and ensuring effective antihemorrhagic activity. Unlike other hemostatic agents, Tranexamic Acid’s effects are more lasting, and it does not interfere with clotting processes, even with prolonged use.

The drug is well absorbed when taken orally, with noticeable effects within 15-30 minutes after administration. It is excreted primarily through the kidneys, ensuring a prolonged antifibrinolytic effect compared to other agents. It is safe and effective when used within therapeutic doses, without causing any significant risk of thrombophilia.

Dosage & Administration:

• Adults:

  • Standard dosage: 500-1000 mg, 3 times daily.
  • For prophylaxis: 0.5-1 gm daily, orally or 500 mg intravenously.
  • For hemorrhagic conditions: 1-3 gm, divided doses. In emergencies, an initial 500 mg intravenous dose may be given, followed by oral doses as necessary.

• Children:

  • For prophylaxis: 5-10 mg per kg of body weight daily, divided into doses.
  • For therapeutic use: 10-20 mg per kg of body weight, with initial intravenous doses at 10 mg/kg, followed by oral doses.

• Elderly: No dose adjustment is needed unless renal failure is present.

Always follow the doctor’s advice for treatment.

Interactions: Xamic is incompatible with penicillin-containing solutions (e.g., Benzyl penicillin). It also antagonizes the antifibrinolytic action of thrombolytic drugs like Streptokinase and Urokinase. The use of estrogen-containing medications may increase the risk of thrombus formation. Avoid direct admixture with whole blood during transfusion.

Contraindications: Do not use Xamic in individuals with hypersensitivity to Tranexamic Acid, thromboembolic disorders, active thrombosis, severe kidney failure, or endocavitary hemorrhages.

Side Effects: Xamic is generally well-tolerated, though some individuals may experience mild side effects like fatigue, conjunctival irritation, nasal congestion, itching, or skin redness. Rarely, postural hypotension, nausea, diarrhea, and gastric discomfort may occur. In case of hypersensitivity reactions, treatment should be suspended immediately, and appropriate therapy initiated.

Pregnancy & Lactation: Xamic should not be used during pregnancy due to potential risks to the fetus. It passes into breast milk in low concentrations, but no significant antifibrinolytic effects are expected in the infant.

Precautions & Warnings:

• Prophylactic treatment should begin 24 hours before surgery and continue for 3-4 days post-surgery.
• In cases of hematuria, reduce doses to prevent clot formation in the urinary tract.
• Use caution in patients with renal dysfunction, cardiopathies, and hepatopathies.
• Always consult your healthcare provider, especially in cases of severe renal insufficiency or anuric syndromes.

Therapeutic Class: Anti-fibrinolytic Drugs, Hemostatic Drugs

Storage Conditions: Store in a dry place at 15-30°C, away from light, and out of reach of children.